CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has submitted its Medical Device license application to Health Canada for review of the INTERCEPT Blood system for plasma. This follows an agreement reached with Health Canada in November of last year to pursue regulatory submissions for both INTERCEPT platelets and plasma. Cerus plans to file its regulatory submission for platelets in the second quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
